Healthcare, Pharma & Life Sciences

75 Million Americans Lack Access to Vascular Surgeon, ACS Data Shows

Image
75 Million Americans Lack Access to Vascular Surgeon, ACS Data Shows

Rosemont, Ill. – September 28, 2026 -- More than 75 million people in the United States live in a county without a vascular surgeon, according to new county-level data released by the American College of Surgeons (ACS), exposing a care gap as the population most vulnerable to vascular disease grows sharply toward 2030, when all baby boomers will be at least 65.

New mapping tool counts just 4,685 vascular surgeons across 3,144 U.S. counties

The ACS Surgical Workforce Mapping Tool, built with the Society for Vascular Surgery (SVS), found an average of 1.4 vascular surgeons per 100,000 people nationwide. While 290 hospital referral regions contain at least one vascular surgeon, 2,320 counties within those same regions have none, showing that regional averages mask local access failures.

Heidi Launches AI Agents to Execute Clinical Admin Tasks, Not Just Log Them

Image
Heidi Launches AI Agents to Execute Clinical Admin Tasks, Not Just Log Them

Melbourne – September 28, 2026 -- Heidi, the AI Care Partner used across global health systems, unveiled Heidi II, a platform upgrade that executes the administrative work surrounding patient visits rather than merely documenting them, the company announced.

Heidi supports 2.8 million weekly patient visits and surfaces 10 million follow-up tasks

Until now those tasks were handed back to clinicians to complete manually. The average doctor spends 8.7 hours a week, or 16.6% of working hours, on administration spread across four to six separate systems per visit, according to Heidi.

Heidi's Scribe has recorded 175 million visits and 67 million clinical hours to date

Heidi Evidence has answered more than 10 million clinical queries since launch, and the platform has surfaced over 400 million follow-on tasks since February 2024.

PrescriberPoint Joins athenahealth Marketplace for AI Prior Authorization

Boston – September 28, 2026 -- PrescriberPoint has joined athenahealth's Partner Community as a Solution Partner, putting its AI-powered prior authorization tool directly into the e-prescribing workflow of more than 170,000 clinicians on the athenaOne network.

Integration lets providers submit prior authorizations without leaving their e-prescribing workflow

The new listing in the athenahealth Marketplace allows providers to initiate and complete prior authorizations using clinical and patient details pulled automatically into the submission. Denied claims can be advanced with appeals and supporting documentation prepared automatically rather than restarted from scratch.

AbbVie Wins FDA Approval for First D1/D5 Parkinson's Drug JUVMO

North Chicago, Ill. – – September 28, 2026 -- AbbVie (NYSE: ABBV) has secured U.S. FDA approval for JUVMO (tavapadon), the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with commercial availability set for October 2026.

JUVMO targets dopamine pathways differently than existing D2/D3 agonists

Roopal Thakkar, AbbVie's chief scientific officer, called the approval the first dopaminergic breakthrough for Parkinson's disease in decades. The once-daily oral tablet can be taken with or without levodopa, positioning it across the full disease continuum rather than a single treatment stage.

Sampled Wins $27.1M VA Contract for Veteran Genomics Program

Image
Sampled Wins $27.1M VA Contract for Veteran Genomics Program

Piscataway, N.J. – September 28, 2026 -- Sampled has secured a five-year contract worth up to $27.1 million from the Department of Veterans Affairs to provide genomics analyses for the Million Veteran Program (MVP), one of the world's largest research initiatives of its kind.

MVP has enrolled more than one million veterans since its 2011 launch

The program studies how molecular factors, lifestyle, and service-related experiences drive elevated veteran health risks, including PTSD, cardiovascular disease, and cancer. Published MVP findings have already advanced understanding of PTSD, artery disease, suicide risk, stroke, and substance use.

Lilly Sets 2040 Deadline to Equalize Diabetes, Obesity Drug Access

Image
Lilly Sets 2040 Deadline to Equalize Diabetes, Obesity Drug Access

Indianapolis – September 28, 2026 -- Eli Lilly and Company (NYSE: LLY) launched the Lilly Change the Course Commitment on Sept. 28, targeting treatment parity for diabetes and obesity patients between high-income countries and resource-limited settings by 2040. Today, for every four patients in high-income countries who access Lilly's diabetes and obesity medicines, only one patient in low- and middle-income countries (LMICs) can reach them.

Lilly targets registration of GLP-1 medicines across Africa, Latin America and Asia

The initiative rests on three pillars: adapting clinical development for resource-limited settings, accelerating registration of innovative medicines including GLP-1s in more LMICs, and strengthening primary health systems through training and digital tools. Lilly said it will prioritize regulatory filings and access pathways in Africa, Latin America and Asia, working with regulators, NGOs and global health organizations.

15.1 Million Americans Lack County-Level General Surgeon Access

Image
15.1 Million Americans Lack County-Level General Surgeon Access

Washington – September 28, 2026 -- More than 15 million Americans live in one of 1,180 US counties with no general surgeon, according to a national analysis unveiled at the ACS Clinical Congress 2026 and published simultaneously in the Journal of the American College of Surgeons.

Study maps 12 surgical specialties across all 3,144 US counties for the first time

The American College of Surgeons (ACS) and the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill identified 201,394 surgeons practicing nationwide as of April 2025, equal to 59.2 surgeons per 100,000 people. Of the country's 3,144 counties, 951 (30%) had no identified surgeon in any of the 12 specialties, affecting 9.6 million people, while 1,180 counties (38%) had no general surgeon, affecting 15.1 million.

Castle Biosciences Study: TissueCypher Test Alters Care 90% of Time

Image
Castle Biosciences Study: TissueCypher Test Alters Care 90% of Time

Friendswood, Texas – September 28, 2026 -- Castle Biosciences, Inc. (Nasdaq: CSTL) said a new peer-reviewed study found its TissueCypher Barrett's Esophagus Test prompted clinicians to change management recommendations in 90% of cases involving patients with non-dysplastic Barrett's esophagus (NDBE).

The case series, published in Foregut: The Journal of the American Foregut Society, evaluated 30 NDBE patients tested as part of clinical care at Keck Medical Center of the University of Southern California (USC).

Test reclassifies risk within a population considered uniformly low-risk

TissueCypher classified 17% of the 30 patients as intermediate or high risk for progression to high-grade dysplasia or esophageal adenocarcinoma within five years, while 83% were confirmed low risk. All patients had received the same NDBE diagnosis prior to testing.

Clorox Launches Purell ProCare, Merging CloroxPro and GOJO for B2B

Image
Clorox Launches Purell ProCare, Merging CloroxPro and GOJO for B2B

Oakland, Calif. – September 28, 2026 -- The Clorox Company has officially launched Clorox Purell ProCare, a new business-to-business health and hygiene platform formed by merging CloroxPro with GOJO, the maker of Purell, following Clorox's acquisition of GOJO earlier in 2026.

Clorox Purell ProCare unifies sales and distribution under one network

The new entity operates a unified sales and service organization alongside a network of distributors, giving professional and healthcare customers access to a combined portfolio spanning Clorox, Purell, Pine-Sol and Glad brands. The business is headquartered in Akron, Ohio, with additional offices in Pleasanton, California, and Toronto, Ontario, plus operations in Ashland, Cuyahoga Falls and Wooster, Ohio, and Alpharetta, Georgia.

Study: Fertility Patients Spend $543, 3 Cycles Before Coverage Starts

Image
Study: Fertility Patients Spend $543, 3 Cycles Before Coverage Starts

New York – September 28, 2026 -- Women trying to conceive spend a median of $543 and track three hormone cycles out of pocket before fertility insurance coverage typically begins, according to a real-world analysis released by Oova and Flora Fertility.

Analysis tracks 49 users who conceived using at-home hormone monitoring

The study examined data from 49 Oova users spanning 2021 to 2026 who subsequently reported a pregnancy. Users tracked a median of four hormone cycles overall, with some spending more than $2,000 across multiple years before conceiving.

Median conception journey runs three cycles, with 73% succeeding within six

Among the group, the median time to conception was three tracked cycles, and 73% conceived within six cycles. The average monitoring spend of roughly $543 compares with a published average of $1,000 for a fertility diagnostic workup and $38,000 for a single IVF cycle.